Myriad Genetics (MYGN) Share-based Compensation (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Share-based Compensation data on file, last reported at $6.5 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $6.5 million, down 31.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $32.2 million (down 31.92% YoY), and the FY2025 annual result was $35.2 million, down 29.32% from the prior year.
• Share-based Compensation climbed to $6.5 million in Q1 2026 per MYGN's latest filing, from $2.8 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $14.5 million in Q2 2024 and troughed at $2.8 million in Q4 2025.
• A 5-year average of $10.0 million and a median of $10.4 million in 2022 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 60.0% in 2024, then plunged 74.31% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $8.2 million in 2022, then rose by 26.83% to $10.4 million in 2023, then grew by 4.81% to $10.9 million in 2024, then sank by 74.31% to $2.8 million in 2025, then jumped by 132.14% to $6.5 million in 2026.
• Business Quant data shows MYGN's Share-based Compensation at $6.5 million in Q1 2026, $2.8 million in Q4 2025, and $12.2 million in Q3 2025.